Trials / Completed
CompletedNCT04460027
W-SUDs for COVID-19
Woebot for Substance Use Disorders During COVID-19
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Woebot Health · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic. This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Woebot Substance Use Disorder | Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation. |
Timeline
- Start date
- 2020-06-22
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
- First posted
- 2020-07-07
- Last updated
- 2022-12-21
- Results posted
- 2022-12-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04460027. Inclusion in this directory is not an endorsement.